Journal of Antimicrobial Chemotherapy (2000) 46, 347-350
© 2000 The British Society for Antimicrobial Chemotherapy
Leading article |
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK
The 1980s and 1990s saw the spread of resistant Grampositive cocci and a lack of new antibiotics directed against them.1 Concern about this situation has spread to governments and the lay press. Nevertheless, pharmaceutical progress has continued amidst the gloom—a point not yet recognized by the pessimists—and rather a lot of new anti-Gram-positive drugs are now progressing. The Table 
summarizes six drugs to have reached or passed Phase II (proof of efficacy). It excludes antibiotics in laboratory research and Phase I. Also excluded are the new quinolones and ketolides, which may offer new options for the treatment of respiratory infections but have borderline activity against most methicillin-resistant Staphylococcus aureus (MRSA) and enterococci.2,3 Linezolid and daptomycin4 are members of new chemical classes with new mechanisms of action. Compounds related to quinupristin/ dalfopristin and evernimicin (everninomicin)5 have been used previously as growth promoters for animals; LY-3333286 is a glycopeptide that retains activity
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Mortin, T. Li, A. D. G. Van Praagh, S. Zhang, X.-X. Zhang, and J. D. Alder Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1787 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum Antipneumococcal Activity of Dalbavancin Compared to Other Agents Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, L. M. Ednie, S. Shapiro, and P. C. Appelbaum Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4210 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, D. Esel, L. M. Kelly, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. M. Ednie, D. B. Hoellman, and P. C. Appelbaum Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3325 - 3333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Y. Yin, L. Lazzarini, F. Li, C. M. Stevens, and J. H. Calhoun Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model J. Antimicrob. Chemother., June 1, 2005; 55(6): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Credito, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide Antimicrob. Agents Chemother., February 1, 2005; 49(2): 770 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ednie, G. Pankuch, and P. C. Appelbaum Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4027 - 4032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4033 - 4036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Hoellman, G. A. Pankuch, and P. C. Appelbaum Antistaphylococcal Activity of CB-181963 (CAB-175), an Experimental Parenteral Cephalosporin Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4037 - 4039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ueda and M. Sunagawa In Vitro and In Vivo Activities of Novel 2-(Thiazol-2-ylthio)-1{beta}-Methylcarbapenems with Potent Activities against Multiresistant Gram-Positive Bacteria Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2471 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum Antianaerobe Activity of RBX 7644 (Ranbezolid), a New Oxazolidinone, Compared with Those of Eight Other Agents Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1143 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Hoellman, G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1148 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Critchley, D. C. Draghi, D. F. Sahm, C. Thornsberry, M. E. Jones, and J. A. Karlowsky Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001 J. Antimicrob. Chemother., March 1, 2003; 51(3): 639 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials J. Antimicrob. Chemother., February 1, 2003; 51(2): 443 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Moellering Jr. Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, January 21, 2003; 138(2): 135 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Moise, A. Forrest, M. C. Birmingham, and J. J. Schentag The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin J. Antimicrob. Chemother., December 1, 2002; 50(6): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Woodford, L. Tysall, C. Auckland, M. W. Stockdale, A. J. Lawson, R. A. Walker, and D. M. Livermore Detection of Oxazolidinone-Resistant Enterococcus faecalis and Enterococcus faecium Strains by Real-Time PCR and PCR-Restriction Fragment Length Polymorphism Analysis J. Clin. Microbiol., November 1, 2002; 40(11): 4298 - 4300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peric, G. Lin, C. L. Clark, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents J. Antimicrob. Chemother., July 1, 2002; 50(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents J. Antimicrob. Chemother., July 1, 2002; 50(1): 101 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Szczypa, K. Betlejewska, K. Nowak, and K. Hryniewicz In vitro activity of linezolid against Gram-positive cocci isolated in Poland J. Antimicrob. Chemother., December 1, 2001; 48(6): 932 - 935. [Full Text] [PDF]
|
|
|
|
|
|
G. G. Rao, A. Steger, and C. M. Tobin Linezolid levels in pancreatic secretions J. Antimicrob. Chemother., December 1, 2001; 48(6): 931 - 932. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Abena, V. G. Mathieux, J.-M. Scheiff, L. M. Michaux, B. C. Vandercam, F. M. Arellano, M. C. Lawyer, E. Z. Lawyer, S. L. Green, and J. C. Maddox Linezolid and Reversible Myelosuppression JAMA, October 24, 2001; 286(16): 1973 - 1974. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Henwood, D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and The Linezolid Study Group Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid J. Antimicrob. Chemother., December 1, 2000; 46(6): 931 - 940. [Abstract] [Full Text] [PDF]
|
|